Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABEO
HOLDAbeona Therapeutics Inc. · Healthcare · United States · $345M · Avg Vol: $9M/d
COMPANY DESCRIPTION
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. The company's competitive advantage is anchored by its proprietary retroviral vector platforms and state-of-the-art, in-house GMP manufacturing facility. Its lead clinical program targets recessive dystrophic epidermolysis bullosa (RDEB), positioning it as a specialized player in the high-value gene therapy sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4M | 3.5M | 0 | 5.8M | 60.3% | 14.5M | 65.5M | 134.9M | 381.5% |
| EPS | -1.72 | -1.18 | -1.55 | 1.34 | — | 0.88 | 1.94 | — | 44.7% |
| Shares | 57.0M | 57.0M | 45.6M | 55.0M | -3.4% | 57.0M | — | — | — |
| Debt | 7.6M | 5.4M | 23.0M | 25.0M | 48.5% | 23.2M | — | — | — |
| Equity | 26.8M | 14.8M | 44.0M | 159.2M | 81.2% | — | — | — | — |
| Op CF | -43.5M | -37.0M | -56.0M | -76.3M | — | -77.7M | — | — | — |
| Inv CF | -24.0M | 0.2M | -39.2M | 105.0M | — | — | — | — | — |
| Fin CF | 43.2M | 37.1M | 104.1M | 26.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABEO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc.(you) | $345M | 58 | HOLD |
| FENC | Fennec Pharmaceuticals Inc. | $347M | 53 | HOLD |
| AGEN | Agenus Inc. | $249M | 61 | HOLD |
| ORMP | Oramed Pharmaceuticals Inc. | $165M | 58 | HOLD |
| RLMD | Relmada Therapeutics, Inc. | $544M | 51 | HOLD |
| IKT | Inhibikase Therapeutics, Inc. | $366M | 41 | HOLD |
| NAGE | Niagen Bioscience, Inc. | $256M | 73 | BUY |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $638M | 67 | BUY |
| TBPH | Theravance Biopharma, Inc. | $874M | 54 | HOLD |
| FBIO | Fortress Biotech, Inc. | $111M | 60 | HOLD |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.7%